

Networking Support Scheme

The anti-IgLON5 disease: Challenges in diagnosis, treatment and pathogenesis of the disease

General information

Dates: 24-25th of February 2022

Workshop Venue: Auditorium Esteve. Center Esther Koplowitz building. Carrer del Rosselló, 153, 08036 Barcelona.



PRELIMINARY PROGRAM

Day 1: CLINICAL AND PATHOLOGICAL ASPECTS OF ANTI-IgLON5 DISEASE

9.00-9.40 Opening of the meeting. Introduction

Chairperson: Francesc Graus

9.00-9.15 Welcome. Francesc Graus. Anti-IgLON5 disease identification and their relevance as an autoimmune and neurodegenerative condition

9.15-9.25 Carles Gaig. From a sleep disorder to a novel neurological disease.

9.25-9.35 Lidia Sabater. From a neuronal antibody to a novel neurological disease

9.35-9.40 Summary. Francesc Graus. Key clinical and physio-pathological features of anti-IgLON5 disease and unsolved issues.

9.40-10.35 Clinical aspects of the anti-IgLON5 disease. Part 1: clinical features at presentation and challenges of the diagnostic.

Chairperson: Joan Santamaria

9.40-9.50 Amaia Muñoz. Sleep and bulbar manifestations

9.50-10.00 Anna Heidbreder. Movement disorders and cognitive dysfunction

10.00-10.30 Round table and audience discussion.

10.30-10.35 Joan Santamaria. Concluding remarks. Future working plans

Coffee break. 10.35-11.00

11.00-12.05 Clinical aspects of the anti-IgLON5 disease. Part 2: clinical features at evolution, and response to treatment.

Chairperson: Josep Dalmau

11.00-11.10 Carles Gaig. The natural history of anti-IgLON5 disease

11.10-11.20 Ilya Ayzenberg. Registry data from GENERATE

11.20-11.30 Marteen Titulaer. Treatment approaches. Paving the way for clinical trials.

11.30-12.00 Round table and audience discussion.

12.00-12.05 Josep Dalmau. Concluding remarks. Future working plans

12.05-13.00 Neuropathological studies and diagnostic criteria.

Chairperson: Romana Hoefftberger

12.05-12.15 Romana Hoefftberger.

12.15-12.25 Ellen Gelpí.

12.25-12.55 Round table and audience discussion.

12.55-13.00 Romana Hoefftberger. Concluding remarks. Future working plan

13.00-15.00 Lunch

15.00-15.50 Neuroimaging

Chairperson: Jan Lewerenz

15.00-15.10 Carsten Finke. Brain magnetic resonance imaging in IgLON5.

15.10-15.20 Thilo van Eimeren. PET Tau imaging in IgLON5

15.20-15.55 Round table and audience discussion.

15.55-15.50 Jan Lewerenz. Concluding remarks. Future working plan.

15.50-17.10 Biomarkers (neurodegenerative/autoimmune)

Chairperson: Frank Leypoldt

15.50-16.05 Frank Leypoldt. Neurodegenerative biomarkers in serum and CSF (Neurofilament light chain and beyond).

16.05-16.15 Daniela Esser. Neuroinflammatory markers in serum and CSF.

16.15-16.25 Inga Konecny. IgG subtypes and clinical correlations.

16.25-17.00 Round table and audience discussion.

17.00-17.10 Frank Leypoldt Concluding remarks. Future working plan

Dinner. 20.00-21.30

Day 2: THE PATHOGENESIS OF THE ANTI-IGLON5 DISEASE

9.00-10.00 Genetic and immunological aspects of the anti-IgLON5 disease: HLA and beyond.

Chairperson: Emmanuel Mignot

9.00-9.10 Selina Yogeshwar. HLA association and its role in anti-IgLON5 disease

9.10-9.20 Gregor Kuhlenbäuer. GWAS data and IgG-ab subtypes

9.20-9.55 Round table and audience discussion.

09.55-10.00 Emmanuel Mignot. Concluding remarks. Future working plan

10.00-11.00 From antibodies to tau phosphorylation

Chairperson: Lidia Sabater

10.00-10.10 Morteen Blaabjerg

10.10-10.20 Jon Landa

10.20-10.55 Round table and audience discussion

10.55-11.00 Lidia Sabater. Concluding remarks. Future working plan

Coffe break. 11.00-11.30

11.30-12.30 Link between Neuroinflammation and Neurodegeneration: Learning from other neurodegenerative diseases?:

Chairperson: Raquel Sánchez del Valle.

11.30-11.40. Antonio Boza. Microglia activation and Neuroinflammation in Neurodegenerative diseases.

11.40-11.50. Harro Seelaar. Neuroinflammatory and neurodegeneration pathways in tauopathies

11.50-12.20 Round table and audience discussion

12.20-12.25 Raquel Sánchez del Valle. Concluding remarks. Future working plan

12.25-12.40 The consortium collaboration agreement. Concluding remarks.

Carles Gaig/Lidia Sabater

